Get the Daily Brief
Latest Biotech News
Regulatory and Industry Leadership Shifts Impacting Biotech
Significant leadership changes and regulatory developments are shaping the biotech landscape. Peter Marks, former FDA Center for Biologics Evaluation and Research head famed for vaccine and gene...
Early Cancer Detection and Diagnostic Technologies
New diagnostic tools and biomarker identification promise earlier and more accurate cancer detection. Owlstone Medical secured up to $49.1 million from ARPA-H to develop accessible,...
FDA Clears Boehringer Ingelheim’s Jascayd for Idiopathic Pulmonary Fibrosis
The U.S. Food and Drug Administration has approved Boehringer Ingelheim’s Jascayd (nerandomilast), a novel oral therapy for idiopathic pulmonary fibrosis (IPF), a rare and fatal lung disease....
Eli Lilly Appoints Former FDA Vaccine Chief Peter Marks to Leadership
Eli Lilly has appointed Dr. Peter Marks, the former director of the FDA’s Center for Biologics Evaluation and Research (CBER), as senior vice president of molecule discovery and head of infectious...
Généthon Advances Affordable Manufacturing of Cell and Gene Therapies
Généthon, a French clinical-stage biotech focusing on rare diseases, aims to make cell and gene therapies (CGTs) both safe and affordable by driving cost-reducing innovations in biomanufacturing....
Clinically Promising Friedreich Ataxia Gene Therapy Nears Accelerated FDA Approval
Lexeo Therapeutics advanced regulatory discussions with the U.S. FDA regarding LX-2006, a gene therapy candidate for Friedreich ataxia cardiomyopathy. Interim clinical data show improvements in...
Insilico Medicine Unveils LEGION AI Workflow for Drug Discovery and IP Protection
Insilico Medicine introduced LEGION, an advanced artificial intelligence platform designed to exhaustively explore chemical space for novel drug molecules. LEGION aims both to discover promising...
Spaceflight Multiomics Uncovers Astronaut Physiological Adaptations Across Missions
Leveraging integrated multiomics data from NASA’s Inspiration4, Polaris Dawn, and Ax-2 space missions, researchers defined molecular signatures associated with human physiological adaptation to...
CT-179: First-In-Class OLIG2 Inhibitor Enters Phase 1 Trials for Brain Tumors
Curtana Pharmaceuticals’ CT-179 is a novel, orally bioavailable small-molecule targeting OLIG2, a transcription factor driving brain tumor stem cells in glioblastoma and SHH-medulloblastoma. The...
Nobel Prize Awarded for Discovery of Regulatory T Cells in Immune Tolerance
The 2025 Nobel Prize in Physiology or Medicine honors Mary Brunkow, Fred Ramsdell, and Shimon Sakaguchi for elucidating regulatory T cells (Tregs), a subset of CD4+ T lymphocytes critical for...
AstraZeneca and Algen Ink $555M AI-Powered Immunology Drug Discovery Deal
AstraZeneca has partnered with San Francisco-based Algen Biotechnologies in a $555 million collaboration leveraging Algen’s AlgenBrain platform, which combines single-cell CRISPR editing and...
MapLight Therapeutics Prepares $227M IPO Amid Government Shutdown Workaround
Neurological disease-focused biotech MapLight Therapeutics progressed plans for a $227 million Nasdaq initial public offering by employing a Securities Act provision allowing registration...
Nobel Prize Awarded for Regulatory T Cell Discovery – Advances Autoimmune Disease Understanding
The 2025 Nobel Prize in Physiology or Medicine has been awarded to Mary E. Brunkow, Fred Ramsdell, and Shimon Sakaguchi for their groundbreaking discoveries on regulatory T cells (Tregs). These...
Eli Lilly Appoints Former FDA Official Peter Marks – Strengthens Infectious Disease and Discovery Efforts
Peter Marks, former head of the FDA's Center for Biologics Evaluation and Research (CBER), has joined Eli Lilly as senior vice president of molecule discovery and head of infectious disease. Marks...
Skye Bioscience's CB1 Inhibitor Fails Phase 2 Weight Loss Trial – Combination Therapy Shows Promise
Skye Bioscience announced that nimacimab, its peripheral cannabinoid receptor 1 (CB1) inhibitor antibody, failed to produce significant weight loss as monotherapy in a 26-week phase 2a trial....
Arbor Biotechnologies and Chiesi Group Forge $2B+ Partnership for Rare Disease Gene Editing
Italian pharmaceutical company Chiesi Group has secured exclusive global rights to Archer Biotechnologies’ ABO-101 gene editing therapy for primary hyperoxaluria type 1 (PH1), an ultra-rare kidney...
Mytos Launches Automated CDMO Facility to Scale Stem Cell Therapy Manufacturing in UK
Mytos, a UK-based cell therapy manufacturing company, has inaugurated its first automated contract development and manufacturing organization (CDMO) facility located within the Cell and Gene...
Insilico Medicine Advances AI Workflow LEGION – Drug Discovery and Intellectual Property Strategy
Insilico Medicine researchers introduced LEGION, a hybrid artificial intelligence workflow combining mechanistic modeling with deep learning, designed to significantly expand chemical space...
Twist Bioscience and Element Biosciences Expand Partnership for Targeted Sequencing Solutions
Twist Bioscience and Element Biosciences extended their collaboration to develop targeted sequencing solutions optimized for Element's AVITI platform. The partnership includes releasing Twist’s...
Aerska Emerges with $21Million Seed Funding to Advance RNAi Therapies for Neurological Diseases
Dublin-based biotechnology startup Aerska has announced a $21 million seed financing led by Age1, Backed VC, and Speedinvest to develop RNA interference (RNAi) therapeutics targeting neurological...